Sequence-specific RNA binding by a Nova KH domain: Implications for paraneoplastic disease and the fragile X syndrome

Cell

Volumn 100, Issue 3, 2000, Pages 323-332

  Lewis, Hal A ^a,b   Musunuru, Kiran ^a   Jensen, Kirk B ^a   Edo, Carme ^a   Chen, Hua ^a   Darnell, Robert B ^a   Burley, Stephen K ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; FRAGILE X SYNDROME; HUMAN; MENTAL DEFICIENCY; NONHUMAN; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN RNA BINDING; PROTEIN STRUCTURE; RNA BINDING; RNA METABOLISM;

EID: 0034603208     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0092-8674(00)80668-6     Document Type: Article

References (59)

1. Albert, M.L., Darnell, J.C., Bender, A., Francisco, L.M., Bhardwaj, N., and Darnell, R.B. (1998). Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4, 1321-1324.
2. Antson, A.A., Dodson, E.J., Dodson, G., Greaves, R.B., Chen, X.-P., and Gollnick, P. (1999). Structure of the trp RNA-binding attenuation protein, TRAP, bound to RNA. Nature 401, 235-242.
3. Baber, J.L., Libutti, D., Levens, D., and Tjandra, N. (1999). High precision solution structure of the C-terminal KH domain of heterogeneous nuclear ribonucleoprotein K, a c-myc transcription factor. J. Mol. Biol. 289, 949-962.
4. Baehrecke, E.H.D. (1997). who encodes a KH RNA binding protein that functions in muscle development. Development 124, 1323-1332.
5. Bogden, C.E., Fass, D., Bergman, N., Nichols, M.D., and Berger, J.M. (1999). The structural basis of terminator recogntion by the Rho transcription termination factor. Mol. Cell 3, 486-493.
6. Brunger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros, P., Grosse-Kunstleve, R.W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N.S., et al. (1998). Crystallography and NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D. Biol. Crystallogr. 54, 905-921.
7. Buckanovich, R.J., and Darnell, R.B. (1997). The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo. Mol. Cell. Biol. 17, 3194-3201.
8. Buckanovich, R.J., Posner, J.B., and Darnell, R.B. (1993). Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron 11, 657-672.
9. Buckanovich, R.J., Yang, Y.Y., and Darnell, R.B. (1996). The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J. Neurosci. 16, 1114-1122.
10. Burd, C.G., and Dreyfuss, G. (1994). Conserved structures and diversity of functions of RNA-binding proteins. Science 265, 615-621.
11. Carson, M. (1991). Ribbons 2.0. J. Appl. Crystallogr. 24, 958-961.
12. Cusack, S. (1997). Aminoacyl-tRNA synthetases. Curr. Opin. Struct. Biol. 7, 881-889.
13. Darnell, R.B. (1996). Onconeural antigens and the paraneoplastic neurologic disorders: At the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. 93, 4529-4536.
14. Darnell, R.B. (1999). The importance of defining the paraneoplastic neurologic disorders. N. Engl. J. Med. 340, 1831-1833.
15. Darnell, R.B., and DeAngelis, L.M. (1993). Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 341, 21-22.
16. De Boulle, K., Verkerk, A.J., Reyniers, E., Vits, L., Hendrickx, J., Van Roy, B., Van den Bos, F., de Graaff, E., Oostra, B.A., and Willems, P.J. (1993). A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat. Genet. 3, 31-35.
17. Deo, R.C., Bonanno, J.B., Sonenberg, N., and Burley, S.K. (1999). Recognition of polyadenylate RNA by the poly(A) binding protein. Cell 98, 835-845.
18. Ding, J., Hayashi, M.K., Zhang, Y., Manche, L., Krainer, A.R., and Xu, R.M. (1999). Crystal structure of the two-RRM domains of hnRNP A1 (UP1) complexed with single-stranded telomeric DNA. Genes Dev. 13, 1102-1115.
19. Dodson, E.J., Winn, M., and Ralph, A. (1997). Collaborative computational project number 8: Providing programs for protein crystallography. Methods Enzymol. 277, 620-633.
20. Ellington, A.D., and Szostak, J.W. (1992). Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. Nature 355, 850-852.
21. Feng, Y., Absher, D., Eberhalt, D.E., Brown, V., Malter, H.E., and Warren, S.T. (1997). FMRP associates with polyribosomes as an mRNP, and the 1304N mutation of severe fragile X syndrome abolishes this association. Mol. Cell 1, 109-118.
22. Fu, Y.H., Kuhl, D.P., Pizzuti, A., Pieretti, M., Sutcliffe, J.S., Richards, S., Verkerk, A.J., Holden, J.J., Fenwick, R.G., Jr., and Warren, S.T. (1991). Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell 67, 1047-1058.
23. Garcia-Mena, J., Das, A., Sanchez-Trujillo, A.,Portier, C., and Montanez, C. (1999). A novel mutation in the KH domain of polynucleotide phosphorylase affects autoregulation and mRNA decay in Escherichia coli. Mol. Microbiol. 33, 235-248.
24. Gedeon, A.K., Baker, E., Robinson, H., Partington, M.W., Gross, B., Manca, A., Korn, B., Poustka, A., Yu, S., and Sutherland, G.R. (1992). Fragile X syndrome without CCG amplification has an FMR1 deletion. Nat. Genet. 1, 341-344.
25. Graus, F., Rowe, G., Fueyo, J., Darnell, R.B., and Dalmau, J. (1993). The neuronal nuclear antigen recognized by the human anti-Ri auto-antibody is expressed in central but not peripheral nervous system neurons. Neurosci. Lett. 150, 212-214.
26. Handa, N., Nureki, O., Kurimoto, K., Kim, I., Sakamoto, H., Shimura, Y., Muto, Y., and Yokoyama, S. (1999). Structural basis for recognition of the tra mRNA precursor by the sex-lethal protein. Nature 398, 579-585.
27. Hendrickson, W. (1991). Determination of macromolecular structures from anomalous diffraction of synchrotron radiation. Science 254, 51-58.
28. Hodel, A.E., Gershon, P.D., and Quiocho, F.A. (1998). Structural basis for sequence-nonspecific recognition of 5′-capped mRNA by a capmodifying enzyme. Mol. Cell 1, 443-447.
29. Hormigo, A., Dalmau, J., Rosenblum, M.K., River, M.E., and Posner, J.B. (1994). Immunological and pathological study of anti-Ri-associated encephalopathy. Ann. Neurol. 36, 896-902.
30. Janin, J. (1995). Principles of protein-protein recognition from structure to thermodynamics. Biochimie 77, 497-505.
31. Jensen, K.B., Musunuru, K., Lewis, H.A., Burley, S.K., and Darnell, R.B. (2000a). The tetranucleotide UCAY directs the specific recognition of RNA by the Nova KH3 domain. Proc. Natl. Acad. Sci. USA, in press.
32. Jensen, K.B., Dredge, B.K. Stefani, G., Zhong, R. Buckanovich, R.J., Okano, H.J., Yang, Y.Y.L., and Darnell, R.B. (2000b). Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability. Neuron, in press.
33. Jones, A.R., and Schedl, T. (1995). Mutations in gld-1, a female germ cell-specific tumor suppressor gene in Caenorhabditis elegans, affect a conserved domain also found in Src-associated protein Sam68. Genes Dev. 9, 1491-1504.
34. Laskowski, R.J., MacArthur, M.W., Moss, D.S., and Thornton, J.M. (1993). PROCHECK: A program to check stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-290.
35. Lewis, H.A., Chen, H., Edo, C., Buckanovich, R.J., Yang, Y.Y., Musunuru, K., Zhong, R., Darnell, R.B., and Burley, S.K. (1999). Crystal structures of Nova-1 and Nova-2 K-homology RNA-binding domains. Structure Fold. Des. 7, 191-203.
36. Lugenbeel, K.A., Peier, A.M., Carson, N.L., Chudley, A.E., and Nelson, D.L. (1995). Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome. Nat. Genet. 10, 483-485.
37. Luque, F.A., Furneaux, H.M., Ferziger, R., Rosenblum, M.K., Wray, S.H., Schold, S.C., Jr., Glantz, M.J., Jaeckle, K.A., Biran, H., and Lesser, M. (1991). Anti-Ri: An antibody associated with paraneoplastic opsoclonus and breast cancer. Ann. Neurol. 29, 241-251.
38. Mahone, M., Saffman, E.E., and Lasko, P.F. (1995). Localized Bicaudal-C RNA encodes a protein containing a KH domain, the RNA binding motif of FMR1. EMBO J. 14, 2043-2055.
39. Musco, G., Stier, G., Joseph, C., Castiglione Morelli, M.A., Nilges, M., Gibson, T.J., and Pastore, A. (1996). Three-dimensional structure and stability of the KH domain: Molecular insights into the fragile X syndrome. Cell 85, 237-245.
40. Musco, G., Kharrat, A., Stier, G., Fraternali, F., Gibson, T.J., Nilges, M., and Pastore, A. (1997). The solution structure of the first KH domain of FMR1, the protein responsible for the fragile X syndrome. Nat. Struct. Biol 4, 712-716.
41. Nagai, K. (1996). RNA-protein complexes. Curr. Opin. Struct. Biol. 6, 53-61.
42. Nussbaum, R.L., and Ledbetter, D.H. (1995). The fragile X syndrome. In Metabolic Basis of Inherited Disease, Seventh Edition, C.R. Scriver, A. Beaudet, W.S. Sly, and D. Valle, eds. (New York: McGraw-Hill), pp. 795-810.
43. Oberle, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boue, J., Bertheas, M.F., and Mandel, J.L. (1991). Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252, 1097-1102.
44. Okano, H.J., Park, W.Y., Corradi, J.P., and Darnell, R.B. (1999). The cytoplasmic Purkinje antigen cdr2 downregulates Myc function: Implications for neuronal and tumor cell survival. Genes Dev. 13, 2087-2097.
45. Ostareck, D.H., Ostareck-Lederer, A., Wilm, M., Thiele, B.J., Mann, M., and Hentze, M.W. (1997). mRNA silencing in erythroid differentiation: hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3′ end. Cell 89, 597-606.
46. Oubridge, C., Ito, N., Evans, P.R., Teo, C.H., and Nagai, K. (1994). Crystal structure at 1.92Å resolution of the RNA-binding domain of the U1A spliceosomal protein complexed with an RNA hairpin. Nature 372, 432-438.
47. Patikoglou, G., and Burley, S.K. (1997). Eukaryotic transcription factor-DNA complexes. Annu. Rev. Biophys. Biomol. Struct. 26, 289-325.
48. Pieretti, M., Zhang, F.P., Fu, Y.H., Warren, S.T., Oostra, B.A., Caskey, C.T., and Nelson, D.L. (1991). Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66, 817-822.
49. Price, S.R., Evans, P.R., and Nagai, K. (1998). Crystal structure of the spliceosomal U2B″-U2A′ protein complex bound to a fragment of U2 small nuclear RNA. Nature 394, 645-650.
50. Rould, M.A., Perona, J.J., and Steitz, T.A. (1991). Structural basis of anticodon loop recognition by glutaminyl-tRNA synthetase. Nature 352, 213-218.
51. thr complex enlightens its represser activity and reveals an essential zinc ion in the active. Cell 97, 371-381.
52. Siomi, H., Matunis, M.J., Michael, W.M., and Dreyfuss, G. (1993a). The pre-mRNA binding K protein contains a novel evolutionarily conserved motif. Nucleic Acids Res. 21, 1193-1198.
53. Siomi, H., Siomi, M.C., Nussbaum, R.L., and Dreyfuss, G. (1993b). The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74, 291-298.
54. Taylor, S.S., and Radzio-Andzelm, E. (1994). Three protein kinase structures define a common motif. Structure 2, 345-355.
55. Terwilliger, T.C., and Berendzen, J. (1997). Bayesian MAD phasing. Acta Crystallogr. D53, 571-579.
56. Tuerk, C., and Gold, G. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 818-822.
57. Valegard, K., Murray, J.B., Stockley, P.G., Stonehouse, N.J., and Liljas, L. (1994). Crystal structure of an RNA bacteriophage coat protein-operator complex. Nature 371, 623-626.
58. Verkerk, A.J., Pieretti, M., Sutcliffe, J.S., Fu, Y.H., Kuhl, D.P., Pizzuti, A., Reiner, O., Richards, S., Victoria, M.F., and Zhang, F. (1991). Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65, 905-914.
59. Yang, Y.Y., Yin, G.L., and Darnell, R.B. (1998). The neuronal RNA-binding protein Nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc. Natl. Acad. Sci. USA 95, 13254-13259.